3 Generic Drug Major, Surfactant and Footwear Stocks With a Strong Future Roadmap: Aurobindo Pharma, Galaxy Surfactants and Redtape
- October 19, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Aurobindo Pharma Rs 1,666.90, P/E 25.46. Galaxy Surfactants Rs 2,502.00, P/E 24.09. Redtape Rs 114.15, P/E 25.49. Closing prices of 14 Oct 2026.
Quick Answer
Generic drug major, surfactant and footwear stocks with the clearest long-term roadmaps today include Aurobindo Pharma in generic formulations and active ingredients sold in the US, Europe and emerging markets, Galaxy Surfactants in surfactants and specialty ingredients for personal care and home care brands and Redtape in footwear, apparel and accessories sold through its own brand stores and online channels. FY26 revenue growth was 5.6% at Aurobindo Pharma, 24.2% at Galaxy Surfactants and 17.5% at Redtape. P/E stands at 25.46 for Aurobindo Pharma (industry 37.59), 24.09 for Galaxy Surfactants (industry 36.60) and 25.49 for Redtape (industry 66.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Generic drug major, surfactant and footwear stocks give investors exposure to medicines, personal care ingredients and footwear sold at home and abroad. Volumes, export demand and margins decide how much of that demand turns into profit.
This list covers three generic drug major, surfactant and footwear stocks: Aurobindo Pharma for generic formulations and active ingredients sold in the US, Europe and emerging markets, Galaxy Surfactants for surfactants and specialty ingredients for personal care and home care brands and Redtape for footwear, apparel and accessories sold through its own brand stores and online channels. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Generic Drug Major, Surfactant and Footwear Stocks?
Generic drug major, surfactant and footwear stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Generic Drug Major, Surfactant and Footwear Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three generic drug major, surfactant and footwear stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Aurobindo Pharma | 1,666.90 | 94,477 | 25.46 | 37.59 | 9.25% | 0.21 |
| Galaxy Surfactants | 2,502.00 | 8,524 | 24.09 | 36.60 | 9.74% | 0.09 |
| Redtape | 114.15 | 6,285 | 25.49 | 66.59 | 23.55% | 0.70 |
Among healthcare, chemicals and consumer stocks, all three trade at a discount to their industry P/E multiples.
Why Do Generic Drug Major, Surfactant and Footwear Stocks Have a Strong Roadmap in India?
Generic drug major, surfactant and footwear stocks have a strong roadmap in India because generic drug demand overseas, personal care brand volumes and branded footwear sales keep adding volumes for these firms. Three drivers stand out.
- Generic demand: Overseas markets buy affordable formulations and ingredients.
- Personal care: Brands buy surfactants for soaps and shampoos.
- Branded footwear: Shoppers upgrade to brand stores and online channels.
Aurobindo Pharma: Generic Formulations and Ingredients Build the Next Leg
Aurobindo Pharma’s roadmap rests on generic formulations and active ingredients sold in the US, Europe and emerging markets, with a wide product basket supporting export revenue.
Revenue grew from Rs 23,775.84 crore in FY22 to Rs 34,145.17 crore in FY26, a 43.6% rise, and FY26 revenue was 5.6% higher than FY25. FY26 net profit rose 0.6% to Rs 3,502.97 crore. Over four years, net profit rose from Rs 2,647.11 crore in FY22 to Rs 3,502.97 crore. In Q1 FY27, revenue grew 18.1% to Rs 9,414.58 crore, and net profit rose 25.2% to Rs 1,032.03 crore. Operating margin was 21.61% in FY26 and 23.10% in Q1 FY27 against 21.95% a year earlier.
Debt to equity is 0.21 and return on equity is 9.25%. FY26 operating cash flow was Rs 5,526.37 crore against capital expenditure of Rs 3,104.67 crore. Aurobindo Pharma paid a dividend of Rs 4 per share for FY26, a yield of 0.25%. At a P/E of 25.46 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 23.10% against 21.61% for FY26, so margin stability is the figure to follow as volumes grow.
Galaxy Surfactants: Personal Care Ingredients Anchor the Roadmap
Galaxy Surfactants’ roadmap rests on surfactants and specialty ingredients for personal care and home care brands, with global consumer companies as customers supporting volumes.
Revenue grew from Rs 3,698.22 crore in FY22 to Rs 5,279.92 crore in FY26, a 42.8% rise, and FY26 revenue was 24.2% higher than FY25. FY26 net profit was Rs 267.38 crore. In Q1 FY27, revenue grew 38.5% to Rs 1,785.18 crore. Operating margin was 9.25% in FY26 and 14.17% in Q1 FY27 against 10.57% a year earlier.
Debt to equity is 0.09 and return on equity is 9.74%. FY26 operating cash flow was Rs 332.66 crore against capital expenditure of Rs 136.95 crore. Galaxy Surfactants paid a dividend of Rs 22 per share for FY26, a yield of 0.91%. At a P/E of 24.09 against an industry P/E of 36.60, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 14.17% against 9.25% for FY26, so margin stability is the figure to follow as volumes grow.
Redtape: A Footwear Brand Anchors the Roadmap
Redtape’s roadmap rests on footwear, apparel and accessories sold through its own brand stores and online channels, with store expansion supporting growth.
FY26 revenue was Rs 2,551.61 crore, 17.5% higher than FY25. FY26 net profit rose 41.5% to Rs 240.55 crore. In Q1 FY27, revenue grew 4.8% to Rs 496.42 crore, and net profit rose 15.2% to Rs 44.48 crore. Operating margin was 20.07% in FY26 and 20.50% in Q1 FY27 against 18.56% a year earlier.
Debt to equity is 0.70 and return on equity is 23.55%. FY26 operating cash flow was Rs 174.01 crore against capital expenditure of Rs 85.92 crore. Redtape paid a dividend of Rs 2 per share for FY26, a yield of 1.76%. At a P/E of 25.49 against an industry P/E of 66.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 20.50% against 20.07% for FY26, so margin stability is the figure to follow as volumes grow.
Best Generic Drug Major, Surfactant and Footwear Stocks in India: Aurobindo Pharma vs Galaxy Surfactants vs Redtape on Key Financials
Among the best generic drug major, surfactant and footwear stocks in India, Aurobindo Pharma leads on FY26 operating margin; Galaxy Surfactants leads on FY26 revenue growth and Q1 FY27 revenue growth; Redtape leads on return on equity and dividend yield. The table puts the numbers side by side.
| Metric | Aurobindo Pharma | Galaxy Surfactants | Redtape |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 34,145.17 | 5,279.92 | 2,551.61 |
| FY26 revenue growth | 5.6% | 24.2% | 17.5% |
| FY26 net profit (Rs Cr) | 3,502.97 | 267.38 | 240.55 |
| FY26 operating profit margin | 21.61% | 9.25% | 20.07% |
| Q1 FY27 revenue growth (YoY) | 18.1% | 38.5% | 4.8% |
| Return on equity | 9.25% | 9.74% | 23.55% |
| P/E ratio | 25.46 | 24.09 | 25.49 |
| Debt to equity | 0.21 | 0.09 | 0.70 |
| Dividend yield | 0.25% | 0.91% | 1.76% |
| FY26 operating cash flow (Rs Cr) | 5,526.37 | 332.66 | 174.01 |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Generic Drug Major, Surfactant and Footwear Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen generic drug major, surfactant and footwear stocks and shortlist generic drug major, surfactant and footwear stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Check the Univest Screener for live data on these generic drug major, surfactant and footwear stocks
Risks to Consider Before Investing in Generic Drug Major, Surfactant and Footwear Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Aurobindo Pharma, Galaxy Surfactants and Redtape live.
Annual reports and quarterly result presentations are the most reliable places to verify the numbers quoted here, because they show segment details, management commentary and the notes behind each figure.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare, chemicals and consumer stocks cover generics, surfactants and footwear. Aurobindo Pharma leads on FY26 operating margin; Galaxy Surfactants leads on FY26 revenue growth and Q1 FY27 revenue growth; Redtape leads on return on equity and dividend yield.
Across generic drug major, surfactant and footwear stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the generic drug major, surfactant and footwear stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Generic Drug Major, Surfactant and Footwear Stocks
Which are the best generic drug major, surfactant and footwear stocks in India with a strong roadmap?
Ans. Aurobindo Pharma, Galaxy Surfactants and Redtape stand out for their roadmaps in generics, surfactants and footwear. FY26 revenue growth was 5.6% at Aurobindo Pharma, 24.2% at Galaxy Surfactants and 17.5% at Redtape, and return on equity ranges from 9.25% to 23.55%.
Is Aurobindo Pharma a good stock to buy now?
Ans. Aurobindo Pharma has a debt to equity ratio of 0.21, a return on equity of 9.25% and a P/E of 25.46 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Aurobindo Pharma, Galaxy Surfactants and Redtape?
Ans. The P/E ratio is 25.46 for Aurobindo Pharma (industry 37.59), 24.09 for Galaxy Surfactants (industry 36.60) and 25.49 for Redtape (industry 66.59). All of them trade below the industry multiple.
Which of these generic drug major, surfactant and footwear stocks has the highest return on equity?
Ans. Redtape has the highest return on equity at 23.55%, followed by Galaxy Surfactants at 9.74% and Aurobindo Pharma at 9.25%.
What are the risks of investing in generic drug major, surfactant and footwear stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did Aurobindo Pharma, Galaxy Surfactants and Redtape perform in Q1 FY27?
Ans. Aurobindo Pharma reported revenue of Rs 9,414.58 crore, up 18.1% year on year, and net profit rose 25.2% to Rs 1,032.03 crore. Galaxy Surfactants reported revenue of Rs 1,785.18 crore, up 38.5% year on year. Redtape reported revenue of Rs 496.42 crore, up 4.8% year on year, and net profit rose 15.2% to Rs 44.48 crore.
Do generic drug major, surfactant and footwear stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 0.25% for Aurobindo Pharma, 0.91% for Galaxy Surfactants and 1.76% for Redtape, based on dividends declared for FY26.
How can I invest in generic drug major, surfactant and footwear stocks in India?
Ans. You can buy generic drug major, surfactant and footwear stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.